UK's Poolbeg Pharma gains on grant of US patent for immunomodulator drugs

Poolbeg Pharma

01/05/2024 13:02

** Shares of Poolbeg Pharma Plc  POLB.L  rise as much as
8.3% to 13.05p, their highest since September 2021
    ** Biopharma company says it received fully-granted patent
from the US Patent Office for its Immunomodulator II patent
application
    ** Co says claims cover a class of drugs, including POLB
001, for treating hypercytokinaemia or excessive activation of
immune cells, and for preventing hypercytokinaemia in a patient
after an immune response has been triggered
    ** Stock up 6.2% as of 1138 GMT, taking YTD gains to ~41%

 (Reporting by Aby Jose Koilparambil in Bengaluru)
 ((abyjose.koilparambil@thomsonreuters.com))